ArticleCureus2025
The Role of E2F Transcription Factor 1 Protein in Multiple Sclerosis (MS): A Comparative Study of Serum Levels in MS Patients and Healthy Controls.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study investigates the role of E2F1 protein levels in patients with multiple sclerosis (MS). Genetic and environmental factors play a role in the pathogenesis of MS, with T and B lymphocytes contributing to tissue damage via immune responses. E2F1, a transcription factor, regulates the cell cycle in T cells and has been associated with autoimmune responses. Methods: This cross-sectional study included 24 MS patients and 21 healthy controls matched for age and gender. Serum E2F1 levels were measured using enzyme-linked immunosorbent assay (ELISA). Clinical and imaging data were collected, including Expanded Disability Status Scale (EDSS) scores, MS subtype classification (RRMS, SPMS, PPMS), and lesion localization on MRI. Statistical analyses were performed to compare E2F1 levels across groups and explore associations with clinical parameters.
resultsIt was observed that E2F1 levels were significantly elevated in the MS group compared to controls (p = 0.011). A subgroup analysis revealed higher E2F1 levels in relapsing-remitting MS (RRMS) than in progressive forms (SPMS and PPMS) (p = 0.024). In addition, female MS patients had significantly higher E2F1 levels than male MS patients (p = 0.028). No significant correlation was found between E2F1 levels and clinical variables such as disease duration or the EDSS score.
conclusionThese findings indicate that E2F1 may play a role in MS pathogenesis, especially in the RRMS subtype, and may act as a biomarker for assessing inflammation and relapse susceptibility. Further research is needed to clarify the role of E2F1 in MS and its potential as a therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.